The drugmakers have filed alirocumab with the FDA, closing the gap between its candidate and Amgen's evolucumab.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
FDA has approved Novartis's Bexsero after approving Pfizer's Trumemba this past October.
Actavis acquires Auden Mckenzie for $459 million; Sanofi/Regeneron's PCSK9 inhibitor could be first to market; Gilead strikes a deal for Harvoni and Sovaldi with four German health insurers.
The CDC and March of Dimes Foundation are asking prescribers to discuss safer alternatives than opioid painkillers for women who may become pregnant.
Brent Saunders, the mind behind the $66 billion acquisition of Allergan, which elevated Actavis to the tenth-largest drugmaker in the world, tells Forbes that growth through acquisition is not simply a short-term tactic but part of a long-term strategy.
Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
Takeda COO Weber refuses Sanofi CEO post; J&J seeks $7.2 billion from Boston Scientific over 10-year old-Guidant acquisition; UCB submits epilepsy drug for US and EU approval.
A novel psoriasis treatment approved today, which demonstrated superiority to TNF inhibitors, could unseat entrenched competitors like Amgen's Enbrel and J&J's Stelara.
The hepatitis C medication will be on the US dustheap, but Merck expects to file a new drug with the FDA later this year.
Marketers may want to dust off plans to create NP-centric materials.
Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.
FDA draws fine line between health and wellness apps; Colorado gives biosimilar swap law another look; ZMapp is set to start human trials of its Ebola vaccine.
CMS head Marilyn Tavenner has resigned; Depomed acquires Nucynta pain pill from J&J; Merck's innovation lead leaves for insurer.
Boehringer Ingelheim announced Thursday that it may sell its Roxane Labs generics business, which Bloomberg says may be worth up to $2.3 billion.
Swedish researchers found rheumatoid arthritis patients tend to drop their first anti-TNF treatment.
A study funded and conducted in part by the CVS Research Institute found that an expansion of prescription-drug benefits could mean better health outcomes as well as reduced spending.
Pharma ad budgets are growing, says IPG; Medical device tax debate rages on; Pfizer has PCSK9 pill in the works.
Clinical trials indicate the CTEP works for specific genetic profiles.
Prime Therapeutics gives Gilead's Harvoni and AbbVie's Viekira Pak preferred formulary status; Novartis and Qualcomm team up for new investment firm; UK cost watchdog axes cancer drug coverage.
Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'
HHS says the government and Seattle Seahawks discussed the PSA soon after the 2014 Superbowl win.
The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.
BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.
A Phase-II study showed the schizophrenia drug performed as well as, but without the weight gain associated with, an older treatment.
AbbVie announced positive interim Phase-III results Thursday for its endometriosis drug elagolix, but one analyst says its commercial impact is likely linked to its effect on patients' bone mineral density.
Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.
The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.
India's Patent Office sets aside Humira patent; Gilead acquires fatty liver disease agent; Bloomberg report says M&A activity likely to persist in 2015.
Clemson University researchers found that patients are not all that honest with healthcare providers.
This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled